Skip main navigation
Close Drawer MenuOpen Drawer Menu
APA Publishing Logo

The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Back to table of contents
Clinical & Research NewsFull Access

New Drugs in Pipeline

Published Online:21 Dec 2001https://doi.org/10.1176/pn.36.24.0017a

In addition to its new Focalin, Novartis Pharmaceuticals is awaiting final approval for an improvement to its long-acting formulation of methylphenidate, Ritalin-SR (see story above). The new Ritalin-LA received its “approvable” notice from the FDA in October. The company expects final approval shortly after the first of the year. It is just one of several developments in the treatment of ADHD.

The new Ritalin-LA is a microbead-technology formulation developed for Novartis by Elan Pharmaceuticals. Each capsule contains 50 percent immediate-release beads and 50 percent extended-release beads. Its efficacy and side-effect profile were shown in company-sponsored clinical trials to not be statistically different from methylphenidate immediate-release multiple dosing.

Noven pharmaceuticals is in the late stages of development of its novel once-daily transdermal methylphenidate system. MethyPatch imbeds methylphenidate into the adhesive used in the skin patch, providing sustained release as long as the patch is worn. It is designed to offer the safety and efficacy of oral immediate-release methylphenidate while eliminating the need for dosing during the school day. In addition, it offers the flexibility of immediately discontinuing dosing of the drug through simply removing the patch. Noven is undertaking a supplemental Stage III clinical trial at multiple centers across the U.S. and hopes to file a New Drug Application (NDA) in the second half of 2002.

Eli Lilly and Company last month filed an NDA for its new ADHD treatment, atomoxetine. The drug will be the first nonstimulant treatment available for ADHD, if approved. The compound appears to be well tolerated in company-sponsored clinical trials, and its efficacy is roughly equivalent to standard stimulant treatments. The new drug is a potent inhibitor of norepinephrine reuptake. Common side effects associated with the drug are headache, abdominal pain, nausea and vomiting, anorexia and weight loss, nervousness, somnolence, and insomnia. In a head-to-head comparison of atomoxetine and methylphenidate, a significantly higher percentage of patients taking atomoxetine experienced vomiting and somnolence than did patients taking methylphenidate.

Each of the products, if approved, would add another option to the arsenal of medications available to augment educational, behavioral, family, and parenting interventions that make up a comprehensive treatment program for ADHD patients.